Matches in SemOpenAlex for { <https://semopenalex.org/work/W2888891493> ?p ?o ?g. }
- W2888891493 endingPage "725" @default.
- W2888891493 startingPage "715" @default.
- W2888891493 abstract "BackgroundInfantile spasms constitute a severe form of epileptic encephalopathy. In the International Collaborative Infantile Spasms Study (ICISS), we showed that combining vigabatrin with hormonal therapy was more effective than hormonal therapy alone at stopping spasms between days 14 and 42 of treatment. In this planned follow-up, we aimed to assess whether combination therapy was associated with improved developmental and epilepsy outcomes at 18 months of age.MethodsIn ICISS, a multicentre, open-label, randomised controlled trial, infants were enrolled from 102 hospitals (three in Australia, 11 in Germany, two in New Zealand, three in Switzerland, and 83 in the UK). Eligible infants had a clinical diagnosis of infantile spasms and a hypsarrhythmic (or similar) electroencephalogram (EEG) no more than 7 days before enrolment. Participants were randomly assigned (1:1) by a secure website to receive hormonal therapy with vigabatrin or hormonal therapy alone. If parents consented, there was an additional randomisation (1:1) of type of hormonal therapy used (prednisolone or tetracosactide depot). Block randomisation was stratified for hormonal treatment and risk of developmental impairment. Parents and clinicians were not masked to therapy, but investigators assessing epilepsy and developmental outcomes at 18 months were masked to treatment allocation. Minimum doses were oral prednisolone 10 mg four times a day or intramuscular tetracosactide depot 0·5 mg (40 IU) on alternate days with or without oral vigabatrin 100 mg/kg per day. The primary outcome at 18 months was development as assessed by the Vineland Adaptive Behaviour Scales (VABS) composite score. Secondary outcomes were the presence or absence of epileptic seizures or infantile spasms in the previous 28 days, as recorded by parents and carers, and the use of any anti-epileptic treatment (including ketogenic diet) in the previous 28 days. Analysis was by intention to treat. The trial is registered with the ISRCTN registry, number 54363174, and EudraCT, number 2006-000788-27.FindingsBetween March 7, 2007, and May 22, 2014, 766 infants were screened and, of those, 377 were randomly assigned to hormonal therapy with vigabatrin (n=186) or hormonal therapy alone (n=191). 362 infants were assessed for developmental and epilepsy outcomes at 18 months, 181 in each treatment group. Mean VABS scores did not differ significantly between the combination therapy group and the hormonal therapy alone group (73·9 [SE 1·3] vs 72·7 [1·4], difference −1·2 [95% CI −4·9 to 2·6], p=0·55). Presence of epilepsy at the assessment at age 18 months was similar in both treatment groups (54 [30·0%] of 180 infants who received combination therapy vs 52 [29·2%] of 178 who received hormonal therapy alone; difference 0·8% [95% CI −8·8 to 10·4], p=0·90). Presence of spasms was also similar in both treatment groups (27 [15·0%] of 180 infants on combination therapy vs 28 [15·7%] of 178 on hormonal therapy alone; difference 0·7% [95% CI −6·9 to 8·3], p=0·85). At the 18-month assessment, 158 (44·1%) of 358 infants were on some form of anti-epileptic treatment. Initial control of spasms between days 14 and 42 of treatment was associated with higher mean VABS scores at 18 months (79·1 [SE 1·2] vs 63·2 [1·1], difference 15·9 [95% CI 12·4 to 19·5], p<0·001) and with higher likelihood of absence of seizures at 18 months (in 39 [17·0%] of 229 infants who achieved spasm cessation vs 67 [51·9%] of 129 who did not; difference 34·9% [24·8 to 45·0], p<0·001). Increasing lead-time to treatment was associated with lower VABS scores (analysis of variance: F[4,354]=6·38, p<0·001) and worse epilepsy outcomes (p=0·023).InterpretationCombination therapy did not result in improved developmental or epilepsy outcomes at 18 months. However, early clinical response to treatment was associated with improved developmental and epilepsy outcomes at 18 months. Longer lead-time to treatment was associated with poorer outcomes. Rapid diagnosis and effective treatment of infantile spasms could therefore improve outcomes.FundingThe Castang Foundation, Bath Unit for Research in Paediatrics, National Institute of Health Research, the Royal United Hospitals Bath NHS Foundation Trust, BRONNER-BENDER Stiftung/Gernsbach, University Children's Hospital Zurich. Infantile spasms constitute a severe form of epileptic encephalopathy. In the International Collaborative Infantile Spasms Study (ICISS), we showed that combining vigabatrin with hormonal therapy was more effective than hormonal therapy alone at stopping spasms between days 14 and 42 of treatment. In this planned follow-up, we aimed to assess whether combination therapy was associated with improved developmental and epilepsy outcomes at 18 months of age. In ICISS, a multicentre, open-label, randomised controlled trial, infants were enrolled from 102 hospitals (three in Australia, 11 in Germany, two in New Zealand, three in Switzerland, and 83 in the UK). Eligible infants had a clinical diagnosis of infantile spasms and a hypsarrhythmic (or similar) electroencephalogram (EEG) no more than 7 days before enrolment. Participants were randomly assigned (1:1) by a secure website to receive hormonal therapy with vigabatrin or hormonal therapy alone. If parents consented, there was an additional randomisation (1:1) of type of hormonal therapy used (prednisolone or tetracosactide depot). Block randomisation was stratified for hormonal treatment and risk of developmental impairment. Parents and clinicians were not masked to therapy, but investigators assessing epilepsy and developmental outcomes at 18 months were masked to treatment allocation. Minimum doses were oral prednisolone 10 mg four times a day or intramuscular tetracosactide depot 0·5 mg (40 IU) on alternate days with or without oral vigabatrin 100 mg/kg per day. The primary outcome at 18 months was development as assessed by the Vineland Adaptive Behaviour Scales (VABS) composite score. Secondary outcomes were the presence or absence of epileptic seizures or infantile spasms in the previous 28 days, as recorded by parents and carers, and the use of any anti-epileptic treatment (including ketogenic diet) in the previous 28 days. Analysis was by intention to treat. The trial is registered with the ISRCTN registry, number 54363174, and EudraCT, number 2006-000788-27. Between March 7, 2007, and May 22, 2014, 766 infants were screened and, of those, 377 were randomly assigned to hormonal therapy with vigabatrin (n=186) or hormonal therapy alone (n=191). 362 infants were assessed for developmental and epilepsy outcomes at 18 months, 181 in each treatment group. Mean VABS scores did not differ significantly between the combination therapy group and the hormonal therapy alone group (73·9 [SE 1·3] vs 72·7 [1·4], difference −1·2 [95% CI −4·9 to 2·6], p=0·55). Presence of epilepsy at the assessment at age 18 months was similar in both treatment groups (54 [30·0%] of 180 infants who received combination therapy vs 52 [29·2%] of 178 who received hormonal therapy alone; difference 0·8% [95% CI −8·8 to 10·4], p=0·90). Presence of spasms was also similar in both treatment groups (27 [15·0%] of 180 infants on combination therapy vs 28 [15·7%] of 178 on hormonal therapy alone; difference 0·7% [95% CI −6·9 to 8·3], p=0·85). At the 18-month assessment, 158 (44·1%) of 358 infants were on some form of anti-epileptic treatment. Initial control of spasms between days 14 and 42 of treatment was associated with higher mean VABS scores at 18 months (79·1 [SE 1·2] vs 63·2 [1·1], difference 15·9 [95% CI 12·4 to 19·5], p<0·001) and with higher likelihood of absence of seizures at 18 months (in 39 [17·0%] of 229 infants who achieved spasm cessation vs 67 [51·9%] of 129 who did not; difference 34·9% [24·8 to 45·0], p<0·001). Increasing lead-time to treatment was associated with lower VABS scores (analysis of variance: F[4,354]=6·38, p<0·001) and worse epilepsy outcomes (p=0·023). Combination therapy did not result in improved developmental or epilepsy outcomes at 18 months. However, early clinical response to treatment was associated with improved developmental and epilepsy outcomes at 18 months. Longer lead-time to treatment was associated with poorer outcomes. Rapid diagnosis and effective treatment of infantile spasms could therefore improve outcomes." @default.
- W2888891493 created "2018-09-07" @default.
- W2888891493 creator A5002114742 @default.
- W2888891493 creator A5002772850 @default.
- W2888891493 creator A5003471800 @default.
- W2888891493 creator A5003728948 @default.
- W2888891493 creator A5004146835 @default.
- W2888891493 creator A5004461693 @default.
- W2888891493 creator A5004491004 @default.
- W2888891493 creator A5004533072 @default.
- W2888891493 creator A5004890585 @default.
- W2888891493 creator A5005251353 @default.
- W2888891493 creator A5006079808 @default.
- W2888891493 creator A5006108953 @default.
- W2888891493 creator A5007143384 @default.
- W2888891493 creator A5007408278 @default.
- W2888891493 creator A5007617672 @default.
- W2888891493 creator A5008772738 @default.
- W2888891493 creator A5008934151 @default.
- W2888891493 creator A5009004267 @default.
- W2888891493 creator A5009070960 @default.
- W2888891493 creator A5009446805 @default.
- W2888891493 creator A5010127348 @default.
- W2888891493 creator A5010225884 @default.
- W2888891493 creator A5010506386 @default.
- W2888891493 creator A5011133106 @default.
- W2888891493 creator A5011635149 @default.
- W2888891493 creator A5011746837 @default.
- W2888891493 creator A5011961987 @default.
- W2888891493 creator A5012062477 @default.
- W2888891493 creator A5012364817 @default.
- W2888891493 creator A5012454732 @default.
- W2888891493 creator A5013008630 @default.
- W2888891493 creator A5013319004 @default.
- W2888891493 creator A5013402283 @default.
- W2888891493 creator A5013996724 @default.
- W2888891493 creator A5014976939 @default.
- W2888891493 creator A5015121297 @default.
- W2888891493 creator A5015407623 @default.
- W2888891493 creator A5015437955 @default.
- W2888891493 creator A5015615770 @default.
- W2888891493 creator A5015965214 @default.
- W2888891493 creator A5016711339 @default.
- W2888891493 creator A5016767742 @default.
- W2888891493 creator A5017032843 @default.
- W2888891493 creator A5017234589 @default.
- W2888891493 creator A5018035642 @default.
- W2888891493 creator A5018224473 @default.
- W2888891493 creator A5018526705 @default.
- W2888891493 creator A5018779172 @default.
- W2888891493 creator A5019035512 @default.
- W2888891493 creator A5019148241 @default.
- W2888891493 creator A5019461993 @default.
- W2888891493 creator A5020453400 @default.
- W2888891493 creator A5021265090 @default.
- W2888891493 creator A5022321780 @default.
- W2888891493 creator A5022874426 @default.
- W2888891493 creator A5023525558 @default.
- W2888891493 creator A5023550670 @default.
- W2888891493 creator A5023585659 @default.
- W2888891493 creator A5023853299 @default.
- W2888891493 creator A5024220427 @default.
- W2888891493 creator A5025079874 @default.
- W2888891493 creator A5026488324 @default.
- W2888891493 creator A5026937975 @default.
- W2888891493 creator A5027451354 @default.
- W2888891493 creator A5027926603 @default.
- W2888891493 creator A5028564169 @default.
- W2888891493 creator A5028786362 @default.
- W2888891493 creator A5028939294 @default.
- W2888891493 creator A5029107850 @default.
- W2888891493 creator A5029270124 @default.
- W2888891493 creator A5029407224 @default.
- W2888891493 creator A5029409166 @default.
- W2888891493 creator A5029425341 @default.
- W2888891493 creator A5030127429 @default.
- W2888891493 creator A5031608864 @default.
- W2888891493 creator A5031707847 @default.
- W2888891493 creator A5033220895 @default.
- W2888891493 creator A5033742500 @default.
- W2888891493 creator A5033754041 @default.
- W2888891493 creator A5034637668 @default.
- W2888891493 creator A5035212508 @default.
- W2888891493 creator A5035456521 @default.
- W2888891493 creator A5036211813 @default.
- W2888891493 creator A5036674043 @default.
- W2888891493 creator A5036810794 @default.
- W2888891493 creator A5036996230 @default.
- W2888891493 creator A5037324383 @default.
- W2888891493 creator A5037489803 @default.
- W2888891493 creator A5037547717 @default.
- W2888891493 creator A5037847953 @default.
- W2888891493 creator A5038373836 @default.
- W2888891493 creator A5038396785 @default.
- W2888891493 creator A5038914339 @default.
- W2888891493 creator A5040167428 @default.
- W2888891493 creator A5040832471 @default.
- W2888891493 creator A5041632865 @default.